1,400
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Testing strategies to reduce morbidity and mortality from Lynch syndrome

, , , , &
Pages 1535-1540 | Received 10 Jun 2018, Accepted 31 Jul 2018, Published online: 20 Dec 2018

References

  • Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path MMR carriers by gene and gender up to 75 years of age: a report from Prospective Lynch Syndrome Database. Gut. 2017;67:1306–1316.
  • Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834.
  • Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–2087.
  • Win AK, Macinnis RJ, Dowty JG, et al. Criteria and prediction models for mismatch repair gene mutations: a review. J Med Genet. 2013;50:785–793.
  • Park JG, Vasen HFA, Park YJ, et al. Suspected HNPCC Criteria in Accordence with the Revised ICG-HNPCC criteria (Amsterdam criteria II): an international collaborative study. Int J Colorectal Dis. 2002;17:109–114.
  • Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.
  • Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–1487.
  • Ramsey SD, Clarke L, Etzioni R, et al. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135:577–588.
  • Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42–65.
  • Vasen HF, Möslein G, Alonso A, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer. 2010;9:109–115.
  • Lagerstedt-Robinsson K, Liu T, Halvarsson B, et al. Diagnostics in a protocol for testing of hereditary non-polyposis colorectal cancer. J Natl Cancer Inst. 2007;99:291–299.
  • Forsberg A, Keränen A, von Holst S, et al. Defining new colorectal cancer syndromes in a population-based cohort of the disease. Anticancer Res. 2017;37:1831–1835.
  • Ghazi S, von Holst S, Picelli S, et al. Colorectal cancer susceptibility loci in a population-based study: associations with morphological parameters. Am J Pathol. 2010;177:2688–2693.
  • Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nuceic aid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
  • Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
  • Thompson BA, Spurdle AB, Plazzer JP, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2014;46:107–115.
  • Lagerstedt-Robinson K, Rohlin A, Aravidis C, et al. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. Oncol Rep. 2016;36:2823–2835.
  • Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–1860.
  • Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.
  • Sie AS, Mensenkamp AR, Adang EM, et al. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Ann Oncol. 2014;25:2001–2007.
  • Veldwijk J, Lambooij MS, Kallenberg FG, et al. Preferences for genetic testing for colorectal cancer within a poöulation-based screening program: a discrete choice experiment. Eur J Hum Genet. 2016;24:361–366.
  • Erten MZ, Fernandez LP, Ng HK, et al. Universal versus targeted screening for Lynch syndrome: comparing ascertainment and costs based on clinical experience. Dig Dis Sci. 2016;61:2887–2895.
  • Severin F, Stollenwerk B, Holinski-Feder E, et al. Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet Med. 2015;17:765–773.
  • Barzi A, Sadeghi S, Kattan MW, et al. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015;107:20.
  • Snowsill T, Huxley N, Hoyle M, et al. A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer. 2015;15:313.
  • Gould-Suarez M, El-Serag HB, Musher B, et al. Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. Dig Dis Sci. 2014;59:2913–2926.
  • Sjursen W, Haukanes BI, Grindedal EM, et al. Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet. 2010;47:579–585.
  • Liljegren A, Lindgren G, Brandberg Y, et al. Individuals with an increased risk of colorectal cancer: perceived benefits and psychological aspects of surveillance by means of regular colonoscopies. J Clin Oncol. 2004;22:1736–1742.